Eye Health News and Research

Latest Eye Health News and Research

Morinda Bioactives releases seven new Fit Body Composition Supplements

Morinda Bioactives recently announced the release of seven new Fit Body Composition Supplements, one of which is Fit Joint.

9 May 2012

Human Gene Therapy highlights new advances in human retinal disease

Gene therapy strategies to prevent and treat inherited diseases of the retina that can cause blindness have progressed rapidly. Positive results in animal models of human retinal disease continue to emerge, as reported in several articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

9 May 2012

Health budget focuses on dental and aged care

The states need to increase the number of public dental patients they treat or lose the reward payments offered by the federal government under its new $500 million dental package. A total of over $800 million of new money has come into the focal points of the health budget - dental and aged care.

9 May 2012

ACADIA first quarter net loss increases to $6.2 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2012.

9 May 2012

Bioactive formulation for optimal eye health

Morinda Bioactives (formerly Tahitian Noni International) recently announced the release of seven new Fit Body Composition Supplements, one of which is Fit Eye. Fit Eye provides an exclusive formulation of highly effective bioactives derived from the most potent sources, including research-recommended levels of lutein, to support optimal eye health.

8 May 2012

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd. entered into a co-promotion agreement for EYLEA aflibercept) Injection in Japan.

From Santen Pharmaceutical Co., Ltd. 8 May 2012

Cellular-level images of the living eye

The same technology used by astronomers to obtain clear views of distant stars is now being used by optometrists to perform incredibly detailed examinations of the living eye.

8 May 2012

Brief empathy training program improves resident physicians interactions with patients

Resident physicians' participation in a brief training program designed to increase empathy with their patients produced significant improvement in how patients perceived their interactions with the residents.

8 May 2012

Amakem presents key preclinical data on AMA0076 at ARVO meeting

Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.

8 May 2012

Metformin blocks uveitis in laboratory rats

University of Texas Medical Branch at Galveston researchers have discovered that a drug already prescribed to millions of people with diabetes could also have another important use: treating one of the world's leading causes of blindness.

8 May 2012

Repeating trinucleotide a strong predictor of Fuchs' dystrophy

Mayo Clinic and University of Oregon researchers have confirmed that a genetic factor called a repeating trinucleotide is a strong predictor of an individual's risk of developing the eye condition Fuchs' dystrophy. The findings were being presented today at the annual conference of the Association for Research in Vision and Ophthalmology in Orlando, Fla.

8 May 2012

Survey: Many people do not know how to spot skin cancer

Doing a little detective work can go a long way in finding skin cancer, the most common form of cancer diagnosed in the United States, at its earliest, most treatable stage. However, a new survey found that many people do not know how to spot skin cancer and are unaware of their risk of developing the disease.

8 May 2012

Cheaper anti-blindness drug could save NHS £85 million annually

Avastin (bevacizumab), which is used to treat wet age-related macular degeneration – the most common cause of blindness among the elderly costs only £60 per injection. But despite trials showing it is no less effective, another drug, Lucentis, is the current official choice, even though it costs £700 per shot. Avastin is intended to treat bowel cancer, but research by the National Institute for Health Research has shown that it also works just as effectively and safely as Lucentis in treating Wet AMD.

8 May 2012

New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting.

8 May 2012

TOKU-E introduces faster dissolving dust-free grade Sodium Dodecyl Sulfate

TOKU-E Company has announced availability of their newly developed, innovative, ultra-safe, faster dissolving dust-free grade (DF) Sodium Dodecyl Sulfate (SDS).

7 May 2012

No functional difference in effects of Lucentis and Avastin on preventing vision loss

The one year results from a study into whether two drug treatments (Lucentis and Avastin), are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD), have been reported today at an international research meeting in Fort Lauderdale, Florida. The findings will also appear online shortly in the leading journal Ophthalmology.

7 May 2012

Automated way to record electrical activity inside neurons in the living brain

Gaining access to the inner workings of a neuron in the living brain offers a wealth of useful information: its patterns of electrical activity, its shape, even a profile of which genes are turned on at a given moment. However, achieving this entry is such a painstaking task that it is considered an art form; it is so difficult to learn that only a small number of labs in the world practice it.

7 May 2012

Eye color linked to high-risk for skin conditions

Eye color may be an indicator of whether a person is high-risk for certain serious skin conditions. A study, led by the University of Colorado School of Medicine, shows people with blue eyes are less likely to have vitiligo.

7 May 2012

Oral nutriceutical restores vision to otherwise hopeless patients facing permanent loss

There may be new found hope for patients whose vision is threatened when medicine injected directly into the eyes fails to cause abnormal blood vessels to recede. While injectable drugs called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered a modern miracle and have become the standard of care for patients with the fast-progressive form of macular degeneration, they are not foolproof.

7 May 2012

Researchers identify new mechanism that causes choroidal neovascularization

Sloppy shipping of a donated human retina to an Indiana University researcher studying a leading cause of vision loss has inadvertently helped uncover a previously undetected mechanism causing the disease. The discovery has led researchers to urge review of how millions of dollars are spent investigating the cause of a type of age-related macular degeneration called choroidal neovascularization.

5 May 2012